Loading
companiesCompany
C4 Therapeutics
Degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53% response rate in heavily pretreated myeloma and entered phase 2 in 2026.
Overview
C4 Therapeutics, based in Watertown, Massachusetts, and listed as CCCC, is a protein degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53 percent response rate in heavily pretreated multiple myeloma and entered phase 2 in 2026. Cemsidomide, built on the MonoDAC platform, with dexamethasone gave that response rate at the 100 microgram dose in relapsed or refractory myeloma at EHA 2026; the phase 2 MOMENTUM trial enrolled its first patient in February 2026 and a phase 1b with elranatamab is ongoing. OnCo links it to multiple myeloma, to PROTACs and molecular glues and glue discovery platforms, to the bottleneck of undruggable drivers, and to ideas on degraders for childhood sarcoma fusion proteins. Whether a next-generation IKZF1/3 degrader beats older drugs of the class in a randomised trial is the open question. The degrader technology page carries the field.
Similar pages
- CompanyKymera Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms.
- CompanyMonte Rosa Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms.
- CompanyNurix Therapeutics
Shares Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms, The undruggable drivers.
- PersonAaron Ciechanover
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Molecular glue discovery platforms, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
- InstitutionTechnion, Israel Institute of Technology
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
- TermImmunomodulatory drugs (IMiDs) and CELMoDs
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
- Key paperDrugging the 'undruggable' cancer targets
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Degraders for the fusion proteins that drive childhood sarcomas, The undruggable drivers.